Interestingly, trastuzumab may also promote immunogenic cell death, resulting in the uptake of breast cancer-associated antigens (BCAA) by dendritic cells (DCs), presentation and elicitation of a CD8+-specific immune response against the BC cells that harbor BCAA. This evidence concerns the gene ARID4B and breast cancer.